Europeiska unionen - svenska - EMA (European Medicines Agency)

teva gmbh - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

newbury pharmaceuticals ab - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

avansor pharma oy - dimetylfumarat - enterokapsel, hård - 240 mg - dimetylfumarat 240 mg aktiv substans; propylenglykol hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

avansor pharma oy - dimetylfumarat - enterokapsel, hård - 120 mg - propylenglykol hjälpämne; dimetylfumarat 120 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

newbury pharmaceuticals ab - fampridin - depottablett - 10 mg - fampridin 10 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hård - 240 mg - natriumlaurilsulfat hjälpämne; natriumbensoat hjälpämne; propylenglykol hjälpämne; cetostearylalkohol hjälpämne; dimetylfumarat 240 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

glenmark arzneimittel gmbh - dimetylfumarat - enterokapsel, hård - 120 mg - dimetylfumarat 120 mg aktiv substans; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; natriumbensoat hjälpämne; cetostearylalkohol hjälpämne

Europeiska unionen - svenska - EMA (European Medicines Agency)

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 och 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.